HRP20100207T1 - Novi kristalni oblici {2-[1-(3,5-bistrifluormetilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}(2-klorfenil)metanona - Google Patents

Novi kristalni oblici {2-[1-(3,5-bistrifluormetilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}(2-klorfenil)metanona Download PDF

Info

Publication number
HRP20100207T1
HRP20100207T1 HR20100207T HRP20100207T HRP20100207T1 HR P20100207 T1 HRP20100207 T1 HR P20100207T1 HR 20100207 T HR20100207 T HR 20100207T HR P20100207 T HRP20100207 T HR P20100207T HR P20100207 T1 HRP20100207 T1 HR P20100207T1
Authority
HR
Croatia
Prior art keywords
pyridin
chlorophenyl
methanone
triazol
bistrifluoromethylbenzyl
Prior art date
Application number
HR20100207T
Other languages
English (en)
Croatian (hr)
Inventor
Borghese Alfio
Scot Coffey David
Kaye Footman Pamela
Wayne Pedersen Steven
Marie Reutzel-Edens Susan
Lenyonga Tameze Shella
Weber Carsten
Timpe Carsten
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20100207T1 publication Critical patent/HRP20100207T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20100207T 2003-10-24 2004-10-12 Novi kristalni oblici {2-[1-(3,5-bistrifluormetilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}(2-klorfenil)metanona HRP20100207T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (1)

Publication Number Publication Date
HRP20100207T1 true HRP20100207T1 (hr) 2010-05-31

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100207T HRP20100207T1 (hr) 2003-10-24 2004-10-12 Novi kristalni oblici {2-[1-(3,5-bistrifluormetilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}(2-klorfenil)metanona

Country Status (28)

Country Link
US (1) US7381826B2 (enExample)
JP (1) JP4959336B2 (enExample)
KR (1) KR100848407B1 (enExample)
CN (1) CN1863791B (enExample)
AR (1) AR046131A1 (enExample)
AT (1) ATE462700T1 (enExample)
AU (1) AU2004285855B8 (enExample)
BR (1) BRPI0415010B8 (enExample)
CA (1) CA2542140C (enExample)
CL (2) CL2009001310A1 (enExample)
CR (1) CR8353A (enExample)
DE (1) DE602004026333D1 (enExample)
DK (1) DK1675846T3 (enExample)
EA (1) EA008881B1 (enExample)
EC (1) ECSP066517A (enExample)
ES (1) ES2340772T3 (enExample)
HR (1) HRP20100207T1 (enExample)
IL (1) IL174926A0 (enExample)
MA (1) MA28329A1 (enExample)
MY (1) MY157375A (enExample)
NO (1) NO335090B1 (enExample)
NZ (2) NZ580480A (enExample)
PE (1) PE20050481A1 (enExample)
PT (1) PT1675846E (enExample)
TW (1) TW200524906A (enExample)
UA (1) UA82901C2 (enExample)
WO (1) WO2005042515A1 (enExample)
ZA (1) ZA200603234B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
KR20170122777A (ko) 2015-03-04 2017-11-06 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
KR20200054232A (ko) 2017-09-13 2020-05-19 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
US20210228555A1 (en) 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
JP2001502311A (ja) * 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬
AR032130A1 (es) * 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
JP4559087B2 (ja) * 2002-04-26 2010-10-06 イーライ リリー アンド カンパニー タキキニン受容体アンタゴニストとしてのトリアゾール誘導体

Also Published As

Publication number Publication date
AR046131A1 (es) 2005-11-23
JP4959336B2 (ja) 2012-06-20
CL2009001311A1 (es) 2009-10-02
NZ545917A (en) 2009-11-27
MY157375A (en) 2016-06-15
NZ580480A (en) 2010-02-26
KR100848407B1 (ko) 2008-07-28
ES2340772T3 (es) 2010-06-09
MA28329A1 (fr) 2006-12-01
CN1863791B (zh) 2011-12-07
CR8353A (es) 2006-06-06
ATE462700T1 (de) 2010-04-15
CL2009001310A1 (es) 2009-12-04
US7381826B2 (en) 2008-06-03
DK1675846T3 (da) 2010-05-31
AU2004285855A1 (en) 2005-05-12
AU2004285855B8 (en) 2011-04-28
TW200524906A (en) 2005-08-01
PT1675846E (pt) 2010-04-20
PE20050481A1 (es) 2005-09-20
CA2542140C (en) 2012-05-29
NO20062371L (no) 2006-05-24
AU2004285855B2 (en) 2010-12-23
CN1863791A (zh) 2006-11-15
EA008881B1 (ru) 2007-08-31
KR20060061388A (ko) 2006-06-07
ZA200603234B (en) 2007-07-25
BRPI0415010A8 (pt) 2018-05-08
IL174926A0 (en) 2006-08-20
NO335090B1 (no) 2014-09-08
DE602004026333D1 (de) 2010-05-12
EA200600829A1 (ru) 2006-08-25
WO2005042515A1 (en) 2005-05-12
CA2542140A1 (en) 2005-05-12
UA82901C2 (en) 2008-05-26
BRPI0415010B1 (pt) 2019-07-09
US20070078166A1 (en) 2007-04-05
ECSP066517A (es) 2006-10-10
BRPI0415010B8 (pt) 2021-05-25
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
HRP20100207T1 (hr) Novi kristalni oblici {2-[1-(3,5-bistrifluormetilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}(2-klorfenil)metanona
ES2634291T3 (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
ES2325140T3 (es) Amidas sustituidas con heterociclos como inhibidores de la calpaina.
AU732653B2 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
CA2160444C (en) Aroyl-piperdine derivatives
US20040006062A1 (en) Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
SK25199A3 (en) Heterocyclic metalloprotease inhibitors
WO2005058884A3 (en) Cyclopropane compounds and pharmaceutical use thereof
KR950032120A (ko) 인간 nk₃수용기의 선택적 길항제인 화합물, 및 의약품 및 진단기구로서의 그의 용도
CA2661166A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
JP2012530703A (ja) 置換ヒドロキサム酸およびその使用
HUT76137A (en) Substituted-aliphatic compounds, process for producing them and pharmaceutical compositions containing the same
ES2278211T3 (es) Derivados de pirazolo 3,4-d pirimidina y su uso en el tratamiento de infeccion por h. pylori.
NO341019B1 (no) Propan-1,3-dion-derivat og salt derav, farmasøytisk preparat, anvendelse til fremstilling av et medikament, samt anvendelse i en fremgangsmåte for behandling
US20040077635A1 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors
NO20016389L (no) Fremgangsmåte for fremstilling av substituerte cyklopentanderivater og nye krystallinske strukturer derav
JP2007509143A5 (enExample)
WO2000058304A1 (en) Heterocyclic sulfonamide derivatives
CA2406829A1 (en) Protease inhibitors
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
RU2335494C2 (ru) Производные бициклических иминокислот в качестве ингибиторов матриксных металлопротеиназ
BRPI0619848A2 (pt) (2,5-dioxoimidazolidin-1-ila)-n-hidróxi-acetamidas como inibidores de metaloproteinase
ES2424356T3 (es) Sales de guanilhidrazona, composiciones, procesos de hacerlas y métodos de uso
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
BRPI0715974A2 (pt) Tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados.